Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 14;17:78. doi: 10.1186/s12871-017-0376-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Time course of liver function markers in patients with ARDS as stratified by antibiotic regime after admission to ICU. Group means are depicted as a bar chart with corresponding standard deviation. a Aspartate aminotransferase activity. The maximum values of each patient (p_max = 0.048) and the average values of the first 10 days (p_1–10 < 0.001) and from days 11–20 (p_11–20 = 0.031) were significantly different between moxifloxacin monotherapy (Moxi-Mono), moxifloxacin combination therapy (Moxi-Combi), and other regimens (Other). In, there was no significant difference between during the last 10 days (p_21–30 = 0.06). b Alanine aminotransferase activity. The maximum values of each patient (p_max = 0.003) and the average values in the first 10 days (p_1–10 < 0.001) and from day 11–20 (p_11–20 = 0.001) were significantly different between moxifloxacin monotherapy, moxifloxacin combination therapy (Moxi-Combi), and other regimens (Other). In contrast, there was no significant difference in the last 10 days (p_21–30 = 0.68). c Direct bilirubin concentration. The maximum values of each patient (p_max = 0.010) and the average values in the first 10 days (p_1–10 < 0.001) were significantly different between moxifloxacin monotherapy (Moxi-Mono), moxifloxacin combination therapy (Moxi-Combi), and other regimens (Other). In contrast, there was no significant difference from day 11–20 (p_11–20 = 0.091) and in the last 10 days (p_21–30 = 0.64)